ArticleDiabetes, obesity & metabolism2025
Tryptophan derivatives as non-invasive diagnostic indicators for obesity-related MASLD in children and adolescents.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Applying Artificial Intelligence to Childhood Obesity: T2DM and MASLD Risk Predictive Models.Diagnostics (Basel, Switzerland) · 2026Review
- Amino Acids-Potential Biomarkers of Histological Features for MASLD in Pediatric Obesity.International journal of molecular sciences · 2026Review
- Altered Tryptophan-Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Insights from LC-MS/MS-Based Metabolite Profiling.International journal of tryptophan research : IJTR · 2026Article
- The role of tryptophan-AhR signaling in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD): implications for therapeutic strategies.Frontiers in immunology · 2026Review
- Tryptophan derivatives as non-invasive diagnostic indicators for obesity-related MASLD in children and adolescents.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) represents a major health burden in children and adolescents with obesity. This study aimed to characterize metabolic alterations associated with obesity-related MASLD and to evaluate the potential of tryptophan (TRP)-derived metabolites as non-invasive biomarkers for early diagnosis. MATERIALS AND
methodsA total of 30 normal-weight individuals and 80 patients diagnosed with obesity were included in the discovery cohort. Circulating metabolites were quantified and compared among normal-weight individuals, patients with obesity, and those with obesity-related MASLD to identify metabolic changes associated with disease status. In vitro experiments using mouse hepatocytes and liver organoids were conducted to assess the effects of TRP-derived metabolites on intracellular lipid accumulation. Finally, a non-invasive diagnostic model was developed using machine learning techniques and validated in an independent cohort of 112 individuals.
resultsCirculating TRP metabolism was markedly elevated in children and adolescents with obesity-related MASLD compared with both normal-weight controls and individuals with simple obesity. TRP-derived metabolites significantly promoted intracellular lipid accumulation in mouse hepatocytes and liver organoids via the induction of oxidative stress. The non-invasive diagnostic model based on TRP-derived metabolites demonstrated robust performance in differentiating obesity-related MASLD from simple obesity in both the discovery and validation cohorts. DISCUSSION: These findings highlight the pivotal role of TRP metabolism in the pathogenesis of MASLD in children and adolescents with obesity. Elevated TRP-derived metabolites may contribute to hepatic lipid accumulation through oxidative stress and serve as promising non-invasive biomarkers for the early diagnosis of obesity-related MASLD. The machine learning-based diagnostic model offers a practical and less invasive alternative to current diagnostic approaches such as liver biopsy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.